CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).
  
  LEARNING OBJECTIVES

  • Personalize the selection of first-line therapy for newly diagnosed MM, considering new clinical research findings and patient- and disease-related factors, including cytogenetic profile and fitness for stem cell transplantation.
  • Appreciate clinical trial data informing the front-line use of CD38-directed monoclonal antibody therapy for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into disease management.
  • Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens for patients with relapsed/refractory MM.
  • Understand the mechanisms of action of and pivotal clinical trial findings with recently FDA-approved novel therapies for MM to facilitate their integration into disease management algorithms.
  • Evaluate the biological rationale for the use of chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as targeted therapy for MM, and identify patients for whom this novel approach should be considered or recommended.
  • Assess available research findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and identify patients for whom treatment with or a clinical trial of one of these novel agents would be appropriate.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for MM, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Rafael Fonseca, MD
  Chief Innovation Officer
  Getz Family Professor of Cancer
  Distinguished Mayo Investigator
  Mayo Clinic in Arizona
  Phoenix, Arizona
  
  Board of Directors: Antengene; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Amgen Inc, Apple Inc, Bristol Myers Squibb, Celgene Corporation, GSK, Janssen Biotech Inc, Karyopharm Therapeutics, Pfizer Inc, RA Capital Management, Regeneron Pharmaceuticals Inc, Sanofi; Data and Safety Monitoring Board/Committee: Bristol Myers Squibb; Scientific Advisory Board: Caris Life Sciences; Stock Options/Stock — Public Company: Antengene.
  
  María-Victoria Mateos, MD, PhD
  Consultant Physician in the Haematology Department
  Associate Professor of Medicine
  Director of the Myeloma Program — Clinical Trials Unit
  University Hospital of Salamanca
  Salamanca, Spain
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR
  Elizabeth O’Donnell, MD
  Director of Early Detection and Prevention
  Dana-Farber Cancer Institute
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committees: Legend Biotech, Natera Inc; Consulting Agreements: Bristol Myers Squibb, Exact Sciences Corporation, Grail Inc, Pfizer Inc, Sanofi, Takeda Pharmaceuticals USA Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, and Sanofi.
  
  Release date: July 2024
  Expiration date: July 2025